HAI Europe Office
Overtoom 60 (2)
1054 HK Amsterdam
The Netherlands
Telephone: + 31 20 683 3684

  • hai_africa
  • hai_asia
  • hai_global
  • ais_us

EU trade secrets directive threat to health, environment, free speech and worker mobility

HAI Europe and 14 NGO partners in multiple sectors opposed the hasty push by the European Commission and Council for a new EU directive on trade secrets. In a joint statement, we called on the Council and European Parliament to amend the definition of a “trade secret” and strengthen the directive's safeguards and exceptions to ensure data that protects the public interest is accessible.

Seven ways the EU could improve access to medicines and biomedical innovation

The European Union’s free trade and R&D policies promote excessive intellectual property protection. This approach jeopardises access to affordable, needed medicines and impedes needs-driven biomedical innovation. HAI Europe, the Médecins Sans Frontières Access Program and Oxfam have developed a set seven recommendations that could improve access to medicines and biomedical innovation in Europe and around the world.

Trading Away Access to Medicines (Revisited) – New report from HAI Europe and Oxfam

A new report by HAI Europe and Oxfam has found that the European Commission is putting the interests of multinational drug companies above those of millions of people with no access to affordable life-saving medicines. The lack of a widely accessible treatment for Ebola, as well as the high price of Hep-C and cancer medicines, show that it's time for the Commission to rethink its trade and innovation policies. Also see our press release.

Investor-to-state dispute settlement in EU-US trade agreement risks access to affordable medicines

HAI Europe, along with several other European and American NGOs, publicly criticised the inclusion of 'investor-to-state dispute settlement' in the Transatlantic Trade and Investment Partnership (TTIP), warning that it will undermine public health policies of European Union Member States and severely jeopardise access to affordable medicines and public health protection. To learn more, read our joint press release and response to the European Commission's public consultation on the issue.

Read more about our commitment to transparency and 2014 Work Plan.